Home › NDC Lookup › RxCUI directory › RxCUI 855205

Docosanol 100 MG/ML Topical Cream [Abreva] — RxCUI 855205

RxNorm drug concept · Semantic branded drug
RxCUI 855205 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 6 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI855205
Official nameDocosanol 100 MG/ML Topical Cream [Abreva]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asAbreva 10 % Topical Cream
FDA products mapped2
Package NDCs mapped6
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Docosanol: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It treats cold sores, also called fever blisters, on your face or lips. It can shorten healing time and how long tingling, pain, burning and itching last.
  • Start at the very first sign, usually a tingle. Early treatment gives the best results. Wash your hands before and after, then rub it in gently but completely.
  • Adults and children 12 and older use it 5 times a day until the cold sore heals. If your child is under 12, check with a doctor first.
  • It can rarely cause a severe allergic reaction, with hives, facial swelling, wheezing, rash or trouble breathing. If that happens, stop and get medical help right away. Do not use...
📖 Read our full Docosanol guide →

🕸️ Concept Web — How Docosanol 100 MG/ML Topical Cream [Abreva] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Docosanol 100 MG/ML Topical Cream [Abreva] RxCUI 855205

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Docosanol 594680
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Abreva 285039
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Docosanol Topical Cream 797533
    • Docosanol Topical Product 1160618
    • Docosanol Topical Cream [Abreva] 855204
    • Abreva Topical Product 1165954
    • Topical Cream 316982
    • Topical Product 1151122
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Docosanol 100 MG/ML Topical Cream SCD · 797534
  • Docosanol 100 MG/ML SCDC · 797532
  • Docosanol Topical Cream SCDF · 797533
  • Docosanol Topical Product SCDG · 1160618

Brand-Name Concepts

  • Docosanol 100 MG/ML [Abreva] SBDC · 855203
  • Docosanol Topical Cream [Abreva] SBDF · 855204
  • Abreva Topical Product SBDG · 1165954
  • Abreva BN · 285039

📦 FDA Products & Package NDCs

2 products · 6 package NDCs
6 package NDCs map to RxCUI 855205 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00135-0200-01 2 g in 1 TUBE (0135-0200-01) ABREVA Haleon US Holdings LLC 2010-03-19
00135-0200-03 2 g in 1 BOTTLE, PUMP (0135-0200-03) ABREVA Haleon US Holdings LLC 2010-03-19
00135-0200-05 2 TUBE in 1 PACKAGE (0135-0200-05) / 2 g in 1 TUBE ABREVA Haleon US Holdings LLC 2017-07-06
00135-0200-06 3 BOTTLE, PUMP in 1 PACKAGE (0135-0200-06) / 2 g in 1 BOTTL... ABREVA Haleon US Holdings LLC 2024-01-02
00135-0300-01 1 TUBE in 1 PACKAGE (0135-0300-01) / 2 g in 1 TUBE ABREVA Haleon US Holdings LLC 2022-03-25
00135-0300-02 2 TUBE in 1 PACKAGE (0135-0300-02) / 2 g in 1 TUBE ABREVA Haleon US Holdings LLC 2022-04-25
Observed labelers: Haleon US Holdings LLC (6) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.